pharmaphorum| News & views on pharma and biotech’s evolving future

Market Access

Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Market Access

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Patients

Deep Dive Rare Disease 2026

Oncology

The future of oncology is adaptive: What ESMO 2026 revealed ...

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

News

Third Rock in $2bn drug-hunting pact with China's Funnel

New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.

Featured Content

Market Access

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Patients

Deep Dive Rare Disease 2026

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Digital

pharmaphorum podcast Episode 284, Mati Gill, AION Labs

AI, start-ups, and the future of human health: AION Labs’ Ma...

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

Oncology

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Sales & Marketing

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Newsletters and Deep Dive
digital magazine

Latest News

News

Third Rock in $2bn drug-hunting pact with China's Funnel

New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.

News

UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D

UK start-up Oyster Therapeutics has raised $60m in first-round financing for its novel take on protein degraders, starting with tau in Alzheimer's.

News

Hims & Hers to offer unapproved peptides to customers

Telehealth firm Hims & Hers will soon start selling some unapproved peptides subject to the FDA's enforcement discretion policy announced last month.

News

FDA orders blindness risk warning to GLP-1 agonist labels

FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to their product labels for a rare eye condition that can cause blindness.

Views & Analysis

Market Access

Biotech's next growth cycle: Renewed confidence comes with c...

Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.

Oncology

The future of oncology is adaptive: What ESMO 2026 revealed ...

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

Market Access

Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Patients

Healthcare wants patients at the centre. So, why are they st...

Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.

Deep Dive

Patients

Deep Dive Rare Disease 2026

Patients

Five diseases that changed rare disease R&D

Patients

Rare diseases are not a niche, but Europe’s opportunity to c...

Rare diseases are individually uncommon, but collectively affect up to 36 million people in the European Union.

Patients

The UK Rare Diseases Framework: Ensuring healthy equity for ...

White Papers & Webinar

Sales & Marketing

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Sales & Marketing

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Digital

IQVIA Technologies White Paper Cover Image

Sponsored

From Automation to Decision Intelligence: The Next Operating...

In this free white paper, IQVIA experts and thought leaders explore the real challenges and bottlenecks in pharmacovigilance today.

Digital

The State of AI in Clinical Trials White Paper

Sponsored

From Pilot to Practice: Insights into AI Adoption, Impact, a...

Read Medidata’s 2nd annual survey, 'The State of AI in Clinical Trials. From Pilot to Practice: Insights into AI Adoption, Impact, and Expectations'.

Podcasts & Video

Oncology

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Digital

AI, start-ups, and the future of human health: AION Labs’ Ma...

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

Oncology

ESMO26: Taiho Oncology on improving the lives of patients wi...

Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Partner Content

PMi Awards 2026: innovation, connection and a changing indus...

One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.

Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences

Partner Content

Rational Based Drug Design Summit Europe

Driving Safer, Faster & More Efficient Discovery Across Europe

Event

Media Partner

Evolution Summit 2027 to Convene Senior Clinical Development...

Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives

Partner Content

ISMAI 2026: Florence to host international symposium on the ...

On 3 and 4 December, in the CTO Auditorium of Careggi University Hospital, clinicians, scientists and international experts will discuss clinical judgement, patient safety and professional acco

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content